EUVIMEDEUVIMED entdecken
Kohortenstudie

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Jessica C Petrov iD, Aakash A Desai, Gursimran S Kochhar, Sheena K Crosby, Jami A Kinnucan, Michael F Picco, Jana G Hashash, Francis A Farraye iD

Inflammatory Bowel Diseases · 12.05.2025 · 31 (5) · 1237-1247

DOI: 10.1093/ibd/izae147 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 12.07.2024. Verfasst von Jessica C Petrov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Colitis, Ulcerative. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metformin exerts anti-inflammatory properties through a positive effect on oxidative stress, gut barrier integrity, and the gut microbiota. Our aim was to evaluate the influence of metformin on inflammatory bowel disease (IBD) outcomes in patients with type 2 diabetes mellitus (T2DM).

Methods

We conducted a retrospective cohort study using the TriNetX database in patients with IBD and T2DM who initiated metformin vs oral hypoglycemics or insulin (control cohort) between August 31, 2002, and August 31, 2022. One-to-one propensity score matching was performed. Primary outcomes were need for intravenous (IV) steroid use or IBD-related surgery within 1, 2, and 3 years after metformin initiation.

Results

Our cohorts included 1323 patients with ulcerative colitis (UC) (mean age 58.7 ± 12.2 years, 50.1% female, 77.3% White) and 1278 patients with Crohn’s disease (CD) (mean age 56.3 ± 12.6 years, 58.2% female, 76.5% White). At 1 year, patients with UC and CD were less likely to require IV steroids (UC: adjusted odds ratio [aOR], 0.45; 95% confidence interval [CI], 0.34-0.59; P < .01; CD: aOR, 0.67; 95% CI, 0.53-0.85; P < .01). The decreased need for IV steroids persisted in all metformin groups at 2 and 3 years. Patients with CD were at a lower risk for IBD-related surgery at year 1 (aOR, 0.5; 95% CI, 0.31-0.81; P < .01), and this finding persisted at 3 years (aOR, 0.62; 95% CI, 0.43-0.89; P < .01). Metformin did not affect risk for surgery in patients with UC.

Conclusions

Patients with IBD and T2DM on metformin had a decreased likelihood of worse IBD outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Hypoglycemic AgentsColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesHumansFemaleMaleRetrospective StudiesMiddle AgedPropensity ScoreAgedAdultTreatment Outcome

Stichwörter der Autor:innen

Crohn’s diseasemetforminulcerative colitis

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.

ORCID-Profile: Jessica C Petrov, Francis A Farraye

Zitieren

APA

Petrov, J. C., Desai, A. A., Kochhar, G. S., Crosby, S. K., Kinnucan, J. A., Picco, M. F., Hashash, J. G., & Farraye, F. A. (2025). Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study. Inflammatory Bowel Diseases, 31(5), 1237-1247. https://doi.org/10.1093/ibd/izae147

Vancouver

Petrov JC, Desai AA, Kochhar GS, Crosby SK, Kinnucan JA, Picco MF, et al. Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study. Inflammatory Bowel Diseases. 2025;31(5):1237-1247. doi:10.1093/ibd/izae147

BibTeX
@article{Petrov2025,
  author = {Petrov, Jessica C and Desai, Aakash A and Kochhar, Gursimran S and Crosby, Sheena K and Kinnucan, Jami A and Picco, Michael F and Hashash, Jana G and Farraye, Francis A},
  title = {Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {5},
  pages = {1237--1247},
  doi = {10.1093/ibd/izae147}
}
Kostenlos starten →